Form 12b-25 Submission Announced By InMed: A Step Closer to Reaching its Goals

InMed Pharmaceuticals Inc. has taken the initiative to file a Form 12b-25 with the SEC in connection with its Quarterly Report on Form 10-Q for the period ending December 31, 2022, demonstrating its commitment to transparency and accountability in financial reporting. As a leader in the research, development, and manufacturing of rare cannabinoids and cannabinoid analogs, InMed is dedicated to providing shareholders with timely and accurate financial updates.

The Company recently announced a change in auditors on December 12, 2022 which has caused a delay in the client acceptance process. As a result, the Company is unable to file its financial statements for the three and six months ended December 31, 2022 in a timely manner. However, the Company will be taking advantage of the five-day extension period afforded by Rule 12b-25 under the Securities Exchange Act of 1934, as amended, to file the Required Filings within the allotted time frame.

Canadian Disclosure Requirements

The Company has applied to the British Columbia Securities Commission for a temporary management cease trade order (MCTO) under National Policy 12-203. This MCTO, if granted, would prohibit trading in the Company’s securities by the Chief Executive Officer and Chief Financial Officer until all relevant filings have been made and the MCTO has been lifted. The general public, who are not insiders of the Company, will still be able to trade in the Company‚Äôs listed securities while the MCTO is in effect. The Company expects to make the Required Filings on or around February 20, 2022 and will comply with the alternative information guidelines set out in sections 9 and 10 of NP 12-203 during the period that the Required Filings are outstanding.

About InMed:

At InMed Pharmaceuticals, we are pioneering the research and development of rare cannabinoids to treat diseases with unmet medical needs. Our cutting-edge clinical and preclinical programs are providing groundbreaking solutions to some of the world’s most pressing health concerns. We are also developing proprietary manufacturing techniques to ensure the production of cannabinoids to meet the demands of the market. Our commitment to innovation and progress makes us a leader in the global healthcare industry.

Leave a Comment